211 related articles for article (PubMed ID: 31000477)
1. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
[TBL] [Abstract][Full Text] [Related]
2. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
Bar KJ; Sneller MC; Harrison LJ; Justement JS; Overton ET; Petrone ME; Salantes DB; Seamon CA; Scheinfeld B; Kwan RW; Learn GH; Proschan MA; Kreider EF; Blazkova J; Bardsley M; Refsland EW; Messer M; Clarridge KE; Tustin NB; Madden PJ; Oden K; O'Dell SJ; Jarocki B; Shiakolas AR; Tressler RL; Doria-Rose NA; Bailer RT; Ledgerwood JE; Capparelli EV; Lynch RM; Graham BS; Moir S; Koup RA; Mascola JR; Hoxie JA; Fauci AS; Tebas P; Chun TW
N Engl J Med; 2016 Nov; 375(21):2037-2050. PubMed ID: 27959728
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
[TBL] [Abstract][Full Text] [Related]
5. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Molina JM; Rizzardini G; Orrell C; Afani A; Calmy A; Oka S; Hinestrosa F; Kumar P; Tebas P; Walmsley S; Grandhi A; Klopfer S; Gendrano I; Eves K; Correll TA; Fox MC; Kim J
Lancet HIV; 2024 Jun; 11(6):e369-e379. PubMed ID: 38734015
[TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
7. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
Lee MJ; Collins S; Babalis D; Johnson N; Falaschetti E; Prevost AT; Ashraf A; Jacob M; Cole T; Hurley L; Pace M; Ogbe A; Khan M; Zacharopoulou P; Brown H; Sutherland E; Box H; Fox J; Deeks S; Horowitz J; Nussenzweig MC; Caskey M; Frater J; Fidler S
Trials; 2022 Apr; 23(1):263. PubMed ID: 35382844
[TBL] [Abstract][Full Text] [Related]
8. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
10. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; Millard KG; Tolstrup M; Jones RB; Conce Alberto WD; Lorenzi JCC; Oliveira TY; Kümmerle T; Suárez I; Unson-O'Brien C; Nogueira L; Olesen R; Østergaard L; Nielsen H; Lehmann C; Nussenzweig MC; Fätkenheuer G; Klein F; Caskey M; Søgaard OS
Lancet Microbe; 2022 Mar; 3(3):e203-e214. PubMed ID: 35544074
[TBL] [Abstract][Full Text] [Related]
11. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
13. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.
Eron JJ; Little SJ; Crofoot G; Cook P; Ruane PJ; Jayaweera D; VanderVeen LA; DeJesus E; Zheng Y; Mills A; Huang H; Waldman SE; Ramgopal M; Gorgos L; Collins SE; Baeten JM; Caskey M
Lancet HIV; 2024 Mar; 11(3):e146-e155. PubMed ID: 38307098
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
[TBL] [Abstract][Full Text] [Related]
15. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
[TBL] [Abstract][Full Text] [Related]
16. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.
Reynolds SJ; Makumbi F; Newell K; Kiwanuka N; Ssebbowa P; Mondo G; Boaz I; Wawer MJ; Gray RH; Serwadda D; Quinn TC
Lancet Infect Dis; 2012 Jun; 12(6):441-8. PubMed ID: 22433279
[TBL] [Abstract][Full Text] [Related]
17. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Stephenson KE; Julg B; Tan CS; Zash R; Walsh SR; Rolle CP; Monczor AN; Lupo S; Gelderblom HC; Ansel JL; Kanjilal DG; Maxfield LF; Nkolola J; Borducchi EN; Abbink P; Liu J; Peter L; Chandrashekar A; Nityanandam R; Lin Z; Setaro A; Sapiente J; Chen Z; Sunner L; Cassidy T; Bennett C; Sato A; Mayer B; Perelson AS; deCamp A; Priddy FH; Wagh K; Giorgi EE; Yates NL; Arduino RC; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
Nat Med; 2021 Oct; 27(10):1718-1724. PubMed ID: 34621054
[TBL] [Abstract][Full Text] [Related]
19. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
20. Combination anti-HIV antibodies provide sustained virological suppression.
Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
